A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers

Status unconfirmed · Phase 3 · Has a placebo group

Conditions studied: Diabetic Foot Ulcers

In brief

The Sponsor of this study, SANUWAVE, Inc., has developed an investigational device known as the dermaPACE® (Pulsed Acoustic Cellular Expression) device for the possible treatment of diabetic foot ulcers. This device generates acoustic (sound) pressure waves designed to act on the cells in your body to generate proteins that may lead to wound closure. The dermaPACE® device has not been approved for the treatment of diabetic foot ulcers; therefore its use in this study is investigational. The purpose of the study is to evaluate the ability of the dermaPACE® device to help diabetic foot ulcers heal more quickly. The active study device, the dermaPACE®, will be compared to an inactive look-alike device (called a "Sham") in this study. The sham device will not provide any treatment to your diabetic foot ulcer.

Key facts

Study ID

NCT01824407

Run by

SANUWAVE, Inc.

People needed

90

Starts

2013-03-01

Last updated by the study team

2014-03-06

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Is >=22 years of age at Visit 1;
• If female of child-bearing potential, both of the following must be met at Visit 1:
• Practices one of the following methods of contraception and continues through the duration of the study: hormonal contraceptives, IUD, spermicide and barrier or implantable device, and
• Has a negative urine qualitative beta-HCG pregnancy test;
• If female and post-menopausal one of the following must be met at Visit 1:
• Has had a complete hysterectomy, bilateral salpingo-oophorectomy or tubal ligation or otherwise be incapable of pregnancy, or
• Is postmenopausal for at least one year;
• Has at least one DFU that is located in the ankle area or below that has persisted a minimum of 30 days prior to Visit 1.
• Has Type I or Type II Diabetes Mellitus with a HbA1c <= 11% at Visit 1;
• Is capable of wound care at home;
• Has a target ulcer >= 1.0 cm2 and <= 16 cm2 at Visits 1 and 2;
• Has a target ulcer that is Grade 1 or 2, Stage A according to the University of Texas Diabetic Wound Classification system, at Visits 1 and 2
• In the leg with the target ulcer has an ABI >= 0.70 and <= 1.20 OR if the ABI is >1.20 has a toe pressure >50 mmHg OR tcpO2 > 40 mmHg at Visit 1;
• Subject agrees, or if applicable, the subject's legal representative agrees that the subject can participate in the study

You may not qualify if…

• Is currently pregnant or plans to become pregnant during the study;
• Is nursing or actively lactating;
• Is morbidly obese (Body Mass Index >= 40) at Visit 1;
• Has clinically significant renal disease defined as having an estimated creatinine clearance of <=40mL/min at Visit 1;
• Has osteomyelitis in the foot or ankle on which the target ulcer is located at Visit 1 or 2;
• Has evidence of a prior ulcer in the same area as the target ulcer;
• Has a target ulcer that has decreased in volume by 50% or more at Visit 2 as compared to the volume at Visit 1;
• Has multiple foot ulcers that are connected by fistulas or has an ulcer(s) that are within 5 cm of the target ulcer at Visit 1 or 2;
• Has a target ulcer that tunnels into wound tracks which cannot be fully visualized from the wound surface at Visit 1 or 2;
• Has active cellulitis either at the site of, or in the surrounding area of, the target ulcer at Visit 1 or 2;
• Has a target ulcer that has visually purulent exudates or that has malodorous exudates on examination at Visit 1 or 2;
• Has PVD, per Doppler Ultrasound, requiring vascular surgery intervention at Visit 1 or 2;
• Requires use of off-loading Diabetic Walker device for the foot intended for study application for a reason other than for a target ulcer on the plantar surface of the foot at Visit 1 or 2;
• Has had a lower extremity revascularization procedure within eight weeks of Visit 1;
• Has active Charcot foot at Visit 1 or 2;
• Has had a surgical procedure to correct biomechanical abnormities within eight weeks of Visit 1;
• Has had a deep vein thrombosis within six months of Visit 1;
• Has clinical evidence of lymphedema at Visit 1;
• Has had chemotherapy within 60 days of Visit 1;
• Has a life expectancy <=2 years;
• Has previously participated in a dermaPACE diabetic foot ulcer study;
• Has had treatment of the target ulcer with growth factors, prostaglandin therapy, negative pressure or vasodilator therapy within two weeks of Visit 1;
• Is receiving >=10 mg/day of steroid therapy;
• Has sickle cell anemia;
• Has a known immunodeficiency disorder to include, but not be limited to: AIDS, HIV, etc.

Where it is running

• Associated Foot and Ankle Specialists — Phoenix, Arizona, United States (enrolling)
• Southern Arizona VA Healthcare System — Tucson, Arizona, United States (enrolling)
• Long Beach VA Healthcare System — Long Beach, California, United States (enrolling)
• Foot and Ankle Clinic — Los Angeles, California, United States (enrolling)
• Alameda County Medical Center - Highlands Campus — Oakland, California, United States (enrolling)
• Lucius J. Hill DPM — San Bernardino, California, United States (enrolling)
• Paul and Margaret Brand Research Center at Barry University — Hialeah, Florida, United States (enrolling)
• The Research Center — Hialeah, Florida, United States (enrolling)
• River City Clinical Research — Jacksonville, Florida, United States (enrolling)
• St. Paul Medical Research — Miami, Florida, United States (enrolling)
• Advanced Pharma CR — Miami, Florida, United States (enrolling)
• Northwestern University, Div of Plastic and Reconstructive Surgery — Chicago, Illinois, United States (enrolling)
• Foot Healthcare Associates — Southfield, Michigan, United States (enrolling)
• Moore Foot and Ankle Specialists — Asheville, North Carolina, United States (enrolling)
• Wound Center - ACMH — Kittaning, Pennsylvania, United States (enrolling)
• Podiatric Medical Partners of Texas — Dallas, Texas, United States (enrolling)
• UT Southwestern Medical Center — Dallas, Texas, United States (enrolling)
• Foot and Ankle Associates of SW Virginia — Roanoke, Virginia, United States (enrolling)
• The Mayer Institute — Hamilton, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.